Introduction
============

Cancer continues being a growing public health problem across the world [@B1]. According to the Cancer Statistics 2018, approximately 1,735,350 new cancer cases, 609,640 death cases were reported worldwide [@B2]. Cancer exists as a complex disease in humans, which is due to the multifaceted interactions among multiple inherited genetic mutations as well as environmental exposures and lifestyle factors [@B3]-[@B5]. Accumulating evidence showed that common mutations or polymorphisms in DNA repair genes involved in altering protein function and capacity to repair damaged DNA, thus deficits in repair capacity which lead to genetic instability, pathogenesis and carcinogenesis, however, the results were inconsistent in distinct cancers, and need further to be elucidated and pay more attention [@B6].

There are less three major DNA repair pathways in humans including nucleotide excision repair (NER), base excision repair (BER), non-homologous end joining (NHEJ) etc, consisting of more than 150 genes [@B7]. The NER is among the classical general damage repair pathways in cells to remove a wide range of bulky DNA lesions induced by environmental mutagens, radiation, and certain chemicals [@B8], [@B9]. The molecular basis of XP has been attributed to mutations in seven XP proteins (A-through-G: XPA, XPB, XPC, XPD, XPE, XPF, and XPG) that are required for NER-mediated removal of DNA damage and XP-variant (XPV)[@B10]. The core XP proteins are involved in different steps of the DNA repair process. XPA protein is the sole recognition factor required for NER activities and is required for sensing DNA damage and initiating the repair process [@B11], [@B12]. The XPC binds to RAD23B to form the XPC-RAD23B complex, which is associated with DNA repair initiation in the NER pathway [@B13]. XPD acts as a 5\'→3\' ATP-dependent dominant that creates a DNA strand opening surrounding the adducted bases in the NER pathway [@B14]. XPF is the endonucleases that perform the dual incisions to release the damaged strand and allow resynthesize using the non-damaged strand as a template [@B15]. Furthermore, WRN protein is one of the members of the RecQ helicase family, which also plays a crucial role in DNA replication and the maintenance of genome stability in non-homologous end joining (NHEJ) DNA repair, homologous recombination repair, and non-homologous end joining (NHEJ) pathway [@B16]. Inactivating mutations or genetic variations in DNA repair genes can modify an individual\'s capacity to repair damaged DNA, and thus lead to the clinical disorder xeroderma pigmentosum (XP) and a predisposition to the development of cancers [@B17], [@B18].

To date, among the core DNA repair genes, there are more than 1000 coding-region SNPs (cSNPs) (<http://www.ncbi.nlm.nih.gov/projects/SNP>) found. Among those cSNPs, a few potential functional SNPs such as located in the 5\'-untranslated regions (5\'UTR) or Exon sites of the candidate genes could change the DNA repair capacity by regulating the transcriptional activity or protein expression, thereby playing critical roles in altering individual\'s susceptibility to cancer. Previous accumulating studies provided evidence about the association of SNPs in DNA repair gene with cancer risk, and most widely studied polymorphism including *XPA* rs2808668 [@B19]-[@B26], rs10817938 [@B21], [@B25], [@B26], *XPC* rs1870134 [@B21], [@B22], [@B26]-[@B31], *XPD* rs238406 [@B32]-[@B54], *XPF* rs3136038 [@B39], [@B55]-[@B63], *WRN* rs1801195 [@B64]-[@B67], rs1346044 [@B64], [@B65], [@B68]-[@B75]. The SNPs *XPA* rs10817938, *XPA* rs2808668 and *XPF* rs3136038 are all the polymorphisms in the site of the gene promoter. The SNP rs10817938 is located in the 5\'-untranslated region (UTR), which is a T to C substitution distant from the transcriptional start site (TSS) about -2718bp, meanwhile, rs2808668 is a T to C substitution located -514bp from the TSS within *XPA* gene, which have been reported novel promoter SNPs in the *XPA* loci associated with cancer risk and development including hepatic cancer (HCC) [@B26], breast cancer [@B19], gastric cancer [@B24], oral squamous cell carcinoma (OSCC) [@B25]. Furthermore the SNP rs3136038 is near the 5\' end of *XPF* gene (also known as ERCC4, excision repair cross-complementation group 4 gene) exhibits remarkably associated with the susceptibility of variety of cancer such as breast cancer [@B55], [@B63], lung cancer [@B56], ESCC [@B61], gastric cancer [@B39], etc. The other selected candidate SNPs *XPC* rs1870134 (Leu16Met), *XPD* rs238406 (Arg156Arg), *WRN* rs1346044 (Cys1367Arg) and *WRN* rs1801195 (Leu1074Phe) are all located in the Exon and Intron sites of the corresponding genes. Recent studies have shown that polymorphisms at Exon 1 (C\>G, rs1870134) of *XPC* gene, Exon 6 (A\>C, rs238406) of *XPD* gene, Exon 34 (C\>T, rs1346044) and Exon 26 (T\>G, rs1801195) of *WRN* gene have been correlated with several types of cancer including breast and prostate cancers [@B29], [@B41], [@B45], [@B46], [@B48], [@B50], [@B64], [@B66], [@B69], [@B70], [@B75], however, these results were inconclusive. Thus, considering the critical role of these genetic variations in the DNA repair genes, and understanding the association between these SNPs and cancer susceptibility is urgently required.

In this study, a comprehensive bioinformatics analysis based on Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) data and meta-analysis was expanded to 7 SNPs of DNA repair genes included 58 eligible case-control studies for evaluating the cancer risk and providing more precise estimation of these associations. We are convinced this review will have important implications in elucidating critical interconnections between DNA repair genes expression, SNPs and cancer risk, and improving the basic understanding of the composition, regulation and function of the DNA repair pathway, eventually paving the way for the development of novel cancer risk evaluation biomarker.

Materials and Methods
=====================

Online public dataset analyses
------------------------------

In the present meta-analysis, online tools including the *Oncomines* (<https://www.oncomine>. org/resource/login.html) and the Gene Expression across Normal and Tumors Tissue (*GENT, <http://medical-genome.kribb.re.kr/GENT/>*) were used to compare the expression of the DNA repair genes between a variety of cancers and their normal controls tissues based on Array Express (<http://www.ebi.ac.uk/microarrayas/ae/>) and GEO datasets. Furthermore, the association of the candidate genes expression with prognosis was assessed by dataset available in Prediction of Clinical Outcomes from Genomic Profiles (PRECOG, *<http://precog.stanford.edu>*). The survival Z-scores for each gene and cancer type were provided by the PRECOG website, and the Log-rank test and HR ratio and 95%CI was established by GEO and Array Express datasets. In addition, genes alterations of these DNA repair genes were represented including mutation, fusion, amplification, deep deletion by using *cBioPortal* tool based on TCGA datasets.

Literature research
-------------------

The present meta-analysis was conducted based on the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. A comprehensive literature search was assessed independently by three authors (S.Q.L, X.Y.H., and W.Y.Q.) in seven electronic databases:*PMC database, PubMed database, the China National Knowledge Infrastructure (CNKI), the Web of Science, Embase, WanFang Date, BIOSIS Preview*, and *ClinicalKey*. All the searched eligible original studies and review articles were reviewed carefully to identify the relevant articles by using the following search terms "rs1346044, Cys1367Arg" or "rs1801195, Leu1074Phe" or "rs2808668" or "rs10817938" or "rs1870134, Leu16Met" or "rs3136038" or "rs238406, Arg156Arg" and "polymorphism or SNP or single nucleotide polymorphism or variation or mutation" and "cancer or carcinoma or tumor or neoplasm", (the search was updated on May 13, 2018). This search was limited to these articles with English or Chinese language, and the results were examined and compared by a third reviewer (Y. L.W.).

Data extraction
---------------

In this meta-analysis, included publications were eligible if they fulfilled the following criteria: 1) the design of case-control study or cohort study; 2) investigated the association of *XPA*, *XPC*, *XPD*, *XPF*, and *WRN* genetic polymorphisms with the cancer risk; 3) provided sufficient genotypic and/or allelic information for estimating the odds ratio (OR) with 95% confidence intervals (CIs); 4) the samples size of cases or controls were ≥20. Excluding the following criteria: (1) animal studies, case reports, reviews, and unpublished results; (2) no case-control study; (3) other mutations and other diseases; (4) lack of adequate information. The data was extracted from each publication in the collection criterion by T.S., Z. K.W, and X.F.W. independently as follows: first author, publication year, ethnicity, country, cancer type, control source (population-based controls, or hospital-based controls based on randomized and prospective), genotyping method, the total number of genotyped cases or controls, and the number of each genotype for cases and controls with each SNP for cancer risk assessment.

Statistical analysis
--------------------

Stata 12.0 software (StataCorp LP, College Station, USA) and Open Meta-Analyst (*<http://www.cebm>. brown. edu/openmeta/*) were used to perform all of the statistical analyses in this meta-analysis. The Hardy-Weinberg equilibrium (*HWE*) was estimated by using the *Chi-square* test or*Fisher\'s* exact test (*P*\<0.05 represented significant deviation) for each control-study. The pooled odds ratios (*OR*s) and their corresponding 95% confidence intervals (*CI*s) were estimated to assess the strength of association between these 7 SNPs and cancer risk. The pooled estimated ORs and CIs were determined by *Z*-test based on homozygote model, additive model, dominant model, and recessive model (*P*\<0.05 represented statistically significant). The heterogeneity between-study was assessed across all eligible comparisons by using *χ*^2^-based Cochran\'s *Q*-test (significant for *P*\<0.10).The random-effects model (*DerSimonian-Laird* method) was chosen if there is statistical heterogeneity. Otherwise the fixed-effects model (*Mantel-Haenszel* method) was used if the studies were homogeneous. *I*^2^ statistics were established from 0% to 100%, which the heterogeneity irrespective of the number of studies (*I*^2^of 25%-55%, 55%-75%, or \>75% represented low, moderate, high heterogeneity). The sensitivity meta-analysis was implemented by omitting each data to reflect the influence of individual datasets to heterogeneity. Publication bias was evaluated by the *Egger*\'s and *Begg-Matzumdar* linear regression tests using asymmetry of the funnel plot (significant for *P*\<0.10).

Results
=======

The mRNA expression of the DNA repair pathway genes in cancers
--------------------------------------------------------------

To identify the potential role of DNA repair pathway genes mRNA expression in different cancers, we used two techniques to estimate associations between these included genes (*XPA*, *XPC*, *XPD*, *XPF*, *WRN*) and mRNA expression. (i) mRNA expression in 13 types of cancers from RNA sequencing dataset platform (*GENT*, *<http://medical-genome.kribb.re.kr/GENT/>*) of tumor samples based on GEO and ArrayExpress datasets was compared to adjacent normal tumor tissues. We found decreased expression of *XPA* in bladder cancer, kidney cancer, liver cancer, lung cancer, prostate cancer, and stomach cancer; *XPC* in blood system cancer, breast cancer, esophageal cancer, kidney cancer, lung cancer and prostate cancer. Elevated expression of *XPD* in bladder cancer, blood system cancer, breast cancer, colorectal cancer, kidney cancer and liver cancer, lung cancer, pancreas cancer, and gastric cancer; *XPF* in brain cancer, colorectal cancer, esophageal cancer, liver cancer, prostate cancer and *WRN* in brain cancer, colorectal cancer, esophageal cancer, kidney cancer, lung cancer, ovarian cancer, and prostate cancer was observed in comparison to normal controls (Figure [1](#F1){ref-type="fig"} A). (ii) The information of the DNA repair pathway genes expression was freely available in *Oncomines* online platform (<https://www.oncomine.org/>) based on TCGA datasets. Then, those genes were evaluated in selected 19 types of cancers datasets and the normal controls, and also found decreased *XPA* and *XPC* expression occurred in majority of tumors, however, *XPD*,*XPF*, and *WRN* genes exhibit increased expression in most of the tumor datasets (Figure [1](#F1){ref-type="fig"} B). Such imbalance expression suggests that those DNA repair genes act as oncogene or tumor suppressor gene in tumorigenesis and progression and maybe exhibit a distinct prognostic impact on survival.

The associations of the DNA repair pathway genes expression with cancer prognosis
---------------------------------------------------------------------------------

To further explore the impact of mRNA expression of DNA repair genes among those included cancers on clinical outcomes, we used dataset available in Prediction of Clinical Outcomes from Genomic Profiles (PRECOG, *<http://precog.stanford.edu>*) based on GEO and Array Express datasets. It was noted that higher expression of *XPA* and *XPC* gene was associated with better overall survival (OS), and the meta survival Z-scores for all cancer were -2.78 and -3.97, respectively (Figure [2](#F2){ref-type="fig"}A). The log-rank test and multivariate Cox proportional hazards regression model analysis further proved that higher expression of *XPA* gene had a better prognosis compared with lower group in glioma cancer (Log-rank test: *P*\<0.0001, HR=0.47, 95%CI=0.36-0.61) and breast cancer (Log-rank test: *P*\<0.0001, HR=0.45, 95%CI=0.24-0.82) (Figure [2](#F2){ref-type="fig"}B). Furthermore, increased *XPC* expression showed significantly protective influence on overall survival including in breast cancer (Log-rank test: *P*\<0.0001, HR=0.51, 95%CI=0.32-0.80) and hematopoietic cancer (Log-rank test: *P*\<0.0001, HR=0.52, 95%CI=0.32-0.87) (Figure [2](#F2){ref-type="fig"}B). However, inversely results were determined that higher expression of *XPD*, *XPF*, and *WRN* gene had a worse impact on OS for all cancers, and the meta Z-scores for all cancer were 1.82, 1.61, and 1.56, respectively (Figure [2](#F2){ref-type="fig"} A). When compared with higher expression group, lower expression of *XPD*, *XPF*, and *WRN* gene showed longer overall survival time for patients with breast cancer, hematopoietic cancer, and neuroblastoma (Log-rank test: P\<0.0001) (Figure [2](#F2){ref-type="fig"}B). These data states that the altered mRNA expression levels of these DNA repair genes might have a distinct correlation with the clinical outcomes.

The characters of the genes dataset altered in cancer samples
-------------------------------------------------------------

These gene alterations of *XPA*, *XPC*, *XPC*, *XPF*, *WRN* were displayed including mutation, fusion, amplification, deep deletion by using *cBioPortal* online tool based on TCGA database(Case Set: 63658 patients/65690 samples). The detail cancer type, mutation fusion amphomdel and alteration frequency of those genes are shown in Figure [3](#F3){ref-type="fig"}. Although the total genetic alteration levels of the candidate genes were not very high only from 0.8%-3% (Figure [3](#F3){ref-type="fig"}A), the alteration frequency showed an higher levels in 33 types of cancers, especially in bladder cancer, BCLA, which were more than 25% (Figure [3](#F3){ref-type="fig"}B). Furthermore, a higher level of duplicate polymorphisms or somatic mutations such as missense, truncating, inframe occurred, which includes 46 SNPs or mutations in *XPA* gene, 91 mutations in *XPC* gene, 227 mutations in *XPD* gene, 210 mutations in *XPF* gene, and 267 mutations in *WRN* gene (Figure [3](#F3){ref-type="fig"}C).These datas suggested that those DNA repair genes alterations probably closely related to the mRNA and protein expression, subsequently involved in affecting the prognosis of cancer patients.

Meta-analysis of the DNA repair genes with cancer risk
------------------------------------------------------

**Figure [S1](#SM0){ref-type="supplementary-material"}** summarizes a flowchart presenting the literature review of study identification, inclusion, exclusion. With the search strategy, a total of 380 published articles was extracted and determined for cancer risk assessment from *PMC database*, *PubMed*, *CNKI*, *CbmWeb, WanFang Date, BIOSIS Preview*. After manually screening abstracts and texts of the included studies, 324 were exempted for 24 lack of adequate information, 54 with other mutations or diseases, 13 abstracts, meta or review, and 233 duplicated publication or overlapping with other publications for further evaluation. Then update 2 studies in Feb 1, 2019. Finally, 58 studies were met the inclusion criteria, 4 studies evaluated the association of *XPA* rs10817938 with cancer risk, 8 reports determined the SNP rs2808668 of *XPA* gene and cancer susceptibility, 8 publications were *XPC* rs1870134 polymorphism, 10 reports studied *XPF* rs3136038 polymorphism, 24 reports determined *XPD* rs238406 SNP, 4 reports and 11 reports analyzed *WRN* rs1801195 and rs1346044, respectively. The distribution of genotypes in the controls for the SNPs of DNA repair genes were in the HWE, except for these 6 publications of Gao, C et al. [@B25] for *XPA* rs2808668, Sun, K for et al. [@B73] for *WRN* rs1346044, Liu, Y for et al. [@B61] for *XPF* rs3136038, Chang, J.S. et al. [@B42]; Szczur, K.P. et al. [@B49]; Miercla, A[@B50] for *XPD* rs238406 (Table [S1](#SM0){ref-type="supplementary-material"}). In this final meta-analysis, *XPA* rs10817938 included 1775 cases and 2156 controls, as well as *XPA* rs2808668 included 2616 cases and 3099 controls. Meanwhile, *XPC* rs1870134, *XPD* rs238406, and *XPF* rs3136038 contained 4987 cases and 6193 controls; 6999 cases and 8652 controls; 5247 cases and 5607 controls, respectively. Moreover, cases and controls for *WRN* rs1801195 and rs1346044 were 3161 and 3142, 6538 and 7657, respectively. The types of cancers chiefly include breast cancer, lung cancer, gastric cancer, hepatocellular cancer, laryngeal cancer, colorectal cancer and esophageal squamous cell cancer (ESCC), prostate cancer, bladder cancer, glioma, basal cell cancer. The ethnicity of the included studies is Asian, Caucasian, Mix and genotyping method includes TaqMan assay, sequencing and PCR-RFLP method. The essential characteristics for all studies were presented in **Table [S1](#SM0){ref-type="supplementary-material"}**.

*XPA* rs10817938, rs2808668 and cancer risk analysis
----------------------------------------------------

The meta-analysis results of the *XPA* rs10817938, rs2808668 polymorphism and cancer risk are shown in Table [1](#T1){ref-type="table"}, Table [S2](#SM0){ref-type="supplementary-material"}, and Figure [4](#F4){ref-type="fig"}, 5, S3, S4. Overall, harboring*XPA* rs10817938 homozygous CC genotype, C allele, and CC/CT genotype in dominant model showed significant association with increased cancer risk \[CC vs.TT in homozygous model: OR (95%CI) = 1.68 (1.02- 2.76), *P* = 0.04; C vs. T allele in additive model: OR (95%CI) = 1.20 (1.04-1.38), *P* = 0.01; and CC/CT vs. TT in dominant model: 1.37 (1.09-1.74), *P* = 0.008\] (Figure [4](#F4){ref-type="fig"}, 5,S3, S4A). Although no association with cancer risk observed in *XPA* rs2808668 SNP with overall analysis, subgroup analysis showed significant decreased cancer risk except for digestive system cancer \[CC vs.TT in homozygous model: OR (95%CI) = 0.71 (0.52-0.98), *P* = 0.04; C vs. T allele in additive model: OR (95%CI) = 0.84 (0.72-0.99), *P* = 0.03; CC vs.TT/TC in recessive model: 0.63 (0.49-0.82), *P*\<0.0001\] (Figure [4](#F4){ref-type="fig"}, 5, S3, S4B).

*XPC*,*XPD*, and*XPF* polymorphism and cancer risk analysis
-----------------------------------------------------------

The effect of *XPC*,*XPD*, and*XPF* polymorphism on cancer risk in overall and subgroup analysis was presented in **Table [1](#T1){ref-type="table"}, Table [S2](#SM0){ref-type="supplementary-material"}** and**Figure [4](#F4){ref-type="fig"}, 5, S3, S4: C, D, and E**. In the overall analysis, the SNP rs238406 of *XPD* gene was associated with an increased overall cancer risk, however, *XPF* rs3136038 showed significantly decreased cancer risk, and no significant association was determined in *XPC* rs1870134 polymorphism. SNP rs238406 AA genotype or A allele carriers showed significantly increased overall cancer risk \[AA vs.CC in homozygote model: OR (95%CI) = 1.20 (1.02-1.41), *P* = 0.03; A vs. C allele in additive model: OR (95%CI) = 1.08 (1.00-1.18), *P*=0.04; and AA vs. CC/CA in recessive model: OR (95%CI) = 1.21 (1.05- 1.40), *P*=0.007\].

Because of the relatively higher heterogeneities (*I*^2^ = 61.1) of rs238406, the further stratification analysis was assessed by using nervous system, basal cell cancer, digestive system, urinary system, genital system and respiratory system cancer, and subsequently, we found significant impact on cancer risk in the subgroup of basal cell cancer \[AA vs.CC in homozygote model: OR (95%CI) = 1.38 (1.05-1.81), *P* = 0.02; A vs. C allele in additive model: OR (95%CI) = 1.18 (1.03- 1.35), *P* = 0.02; and AA vs. CC/ CA in recessive model: OR (95%CI) = 1.30 (1.03-1.65), *P* = 0.03\], however no association observed with cancer risk in the other groups. Furthermore, only patients with prostate cancer carrying *XPC* rs1870134 C allele or CC/CG genotype in the dominant model are associated with decreased cancer risk \[C vs. G allele in additive model: OR (95%CI) = 0.82 (0.72- 0.95), *P* = 0.007; CC/CG vs.GG in dominant model: 0.77 (0.65-0.92), *P* = 0.004\]. Moreover, *XPF* rs3136038 polymorphism was associated with decreased overall cancer risk in the patients with additive model \[OR (95%CI) = 0.91 (0.86-0.96), *P* = 0.001, Table [1](#T1){ref-type="table"}\] and dominant model \[OR (95%CI) = 0.89 (0.81-0.98), *P* = 0.02, Table [S2](#SM0){ref-type="supplementary-material"}\]. More importantly, similar results were found in the stratification group of digestive system cancer patients who harboring TT genotype \[OR (95%CI) = 0.64 (0.48-0.87), *P* = 0.004\], T allele in additive model \[OR (95%CI) = 0.82 (0.72- 0.94), *P* = 0.003\], dominant model \[OR (95%CI) = 0.81 (0.68-0.96), *P*=0.02\] and recessive model \[OR (95%CI) = 0.70 (0.52-0.96), *P* = 0.025\] significantly decreased cancer risk, however, there was no association observed in other subgroups.

*WRN* rs1801195, rs1346044 and cancer risk analysis
---------------------------------------------------

Although no significant association between polymorphisms of *WRN* rs1801195, rs1346044 and cancer risk in overall meta-analysis results was found, the further stratification analysis showed significantly increased cancer risk in the genital system subgroup patients with rs1801195 genotype and breast cancer with rs1346044 genotype, as shown in **Table [1](#T1){ref-type="table"}, Table [S2](#SM0){ref-type="supplementary-material"}** and **Figure [4](#F4){ref-type="fig"}, 5, S3, S4: F and G**. For SNP rs1801195, genital system cancer patients correlated with increased cancer risk when carrying TT genotype \[OR (95%CI) = 1.37 (1.08-1.73), *P*=0.009\], T allele \[OR (95%CI) = 1.15 (1.02-1.29), *P* = 0.02\], and recessive model \[OR (95%CI) = 1.44 (1.17-1.78), *P* = 0.001\]. Moreover, breast cancer patients with rs1346044 CC genotype \[OR (95%CI) = 1.47 (1.10-1.97), *P* = 0.010\], C allele \[OR (95%CI) = 1.15 (1.04-1.26), *P* = 0.005\], dominant model\[OR (95%CI) = 1.14 (1.02-1.28), *P* = 0.018\] and recessive model \[OR (95%CI) = 1.37 (1.03-1.83), *P* = 0.03\] significantly correlated with elevated cancer susceptibility.

Heterogeneity and sensitivity analysis
--------------------------------------

In this meta-analysis, no significant heterogeneities were found in the overall analysis of *XPA* rs10817938, rs2808668, *XPC* rs1870134, *XPF* rs3136038, and *WRN* rs1801195. However, the moderate heterogeneity was observed when all the studies were analyzed for all the cases of *XPD* rs238406 under the homozygous model (*I*^2^ = 61.1%) and *WRN* rs1346044 under the homozygous model (*I*^2^ = 61.7%) (Table [1](#T1){ref-type="table"}, Table [S2](#SM0){ref-type="supplementary-material"}). After stratification analysis, the heterogeneity of SNP rs238406 was found accused of the nervous system cancer and urinary system cancer, which is available in the higher *I*^2^ value, 82.9% and 93.2%, respectively. For another SNP rs1346044, the heterogeneity exists the subgroup of digestive system cancer (*I*^2^ = 82.3%), and other subgroups showed no heterogeneity (**Figure [4](#F4){ref-type="fig"}, 5, S3, S4 G**).

Publication bias analysis
-------------------------

In this included meta-analysis, the Begg\'s funnel plot and Egger\'s test were determined to evaluate the publication bias of the studies. We found no significantly publication bias was observed for all the dominant models of the seven SNPs (*XPA* rs10817938: *P*=0.289; *XPA* rs2808668: *P*=0.673; *XPC* rs1870134: *P*= 0.763; *XPD* rs238406: *P*=0.09, *XPF* rs3136038: *P*=0.245; *WRN* rs1801195: *P*=0.722; and *WRN* rs1346044: *P*=0.966) by the Egger\'s test. The funnel plots shapes showed obvious symmetry, which were obtained for the association of the seven SNPs (*XPA* rs10817938: *P*=0.734; *XPA* rs2808668: *P*=0.902; *XPC* rs1870134: *P*= 0.711; *XPD* rs238406: *P*=0.107, *XPF* rs3136038: *P*=0.152; *WRN* rs1801195: *P*=0.497; and *WRN* rs1346044: *P*=0.929) (**Figure [S2](#SM0){ref-type="supplementary-material"}**). The data indicated that no publication bias might be under a significant influence on the observed effect of SNPs located at DNA repair genes on susceptibility of cancer as assessed.

Discussion
==========

In humans, DNA repair systems act fundamental function in maintenance of cellular genomic integrity in facing the environmental insults, DNA replication errors, and their interactions, thereby the dysregulation lead to a significantly alteration in individual susceptibility to cancer [@B7]. Previous accumulating studies established that aberrant expression of the core DNA repair genes such as *XPs* and *WRN* can modulate the capability of DNA damage and/or repair and subsequently contribute to carcinogenesis [@B76]-[@B79]. In our bioinformatics analysis, we confirmed that the critical proteins of DNA damage pathway was significantly associated with carcinogenesis, and lower *XPA* and *XPC* mRNA levels, higher *XPD*,*XPF*, and *WRN* expression levels were observed in majority of included 19 types of cancers compared with the normal control tissues. These data suggested that downregulated oncogenes of *XPA*, *XPC* or upregulated tumor suppressor genes such as*XPD*,*XPF*, and *WRN* may be involved in promoting carcinogenesis via impairment of DNA repair. Since distinct expression levels of candidate genes are the essence of affecting cancer prognosis, we further found that elevated expression of *XPA* and *XPC* had a better impact on cancer survival time, in contrast, higher expression of *XPD*, *XPF*, and *WRN* showed significantly worse influence on overall survival in overall meta Z-scores analysis. More importantly, these genes alteration frequency displayed higher levels in 33 types of cancers. So we hypothesized that the genetic variations of DNA repair core genes, especially in the 5\'UTR (*XPA* rs10817938 and rs2808668, *XPF* rs3136038) or Exon sites (*XPC* rs1870134, *XPD* rs238406, *WRN* rs1346044 and rs1801195) may play a critical role in altering protein function and capability to repair damaged DNA, thus affecting the cancer risk.

NER is a multiple protein mediated sequential DNA damage repair process, and XPA, a 32kDa zinc-finger DNA-binding protein, is the sole recognition factor required its damage verification and initiation in NER activities [@B13]. Recent studies reported that the potentially functional SNPs in the *XPA* gene, especially in the transcription factors binding sites (TFBS) such as novel SNPs rs10817938 and rs2808668, which located at the *XPA* prompter region and may be involved in the cancer risk[@B19]-[@B26], [@B29]. For instance, Gao et al. [@B25] reported that the risk effect of rs10817938 T to C substitution not only had a strong impact on transcription activity, *XPA* mRNA and protein expression, but also obviously showed a significant gene-environment interaction with the smoking status of the patients. In the present meta-analysis, 1775 cases and 2156 controls included for SNP rs10817938, a significantly increased cancer risk was observed harboring CC, CC/CT genotype, or C allele on the overall analysis as well as the stratification analysis in the digestive system cancers. However, no significant association was observed between rs2808668 and cancer susceptibility in the overall analysis, and 8 studies were included with 2616 cases and 3099 controls. Thereafter stratified analyses showed that carrying *XPA* rs2808668 homozygous CC genotype or C allele was associated with significantly decreased cancer risk in the subgroup of including lung cancer and breast cancer except for digestive system cancer. Recent studies reported that *XPA* rs2808668 can interact with environmental factor such as drinking in gastric cancer, and clinicopathological parameters such as tumor size, metastatic status at onset and mitotic index in gastrointestinal stromal cancer [@B21], [@B24]. These findings highlight an obvious divergence between the SNP rs2808668 or rs10817938and cancer risk, although these SNPs were all in the *XPA* promoter region, which might be partially explained by environmental factors or clinicopathological parameters interacted with genetic variants synergistically contributing to the carcinogenesis.

XPC, a 106 kDa protein, is another primary damage recognition factor required for the global genome NER repair pathway, which can form a tight heterodimeric complex with HR23B, and to be indispensable for the stability of each protein as well as damage recognition function of XPC [@B13]. Following the initial damage recognition step, XPD, an 87 kDa protein, is an ATP-dependent helicase and serves as the dominant helicase in NER repair pathway [@B14]. Next, endonuclease is required for NER steps, XPF, a 103 kDa protein, is structure-specific nuclease that recognizes the DNA junction 5\' to the adducted base(s) [@B15]. Thus, these XPs proteins act their function in the different steps of NER process including damage recognition, opening of the DNA surrounding the damaged base, and removal of the damaged oligonucleotides. In this pooled meta-analysis, 8 studied in 4987 cases and 6193 controls for *XPC* rs1870134, 24 studies with 6999 cases and 8652 controls for *XPD* rs238406, and 10 studies of 5247 cases and 5607 controls for *XPF* rs3136038 polymorphisms were recruited. A significantly increased overall cancer risk was observed in the patients with *XPD* rs238406 AA homozygous or A allele, but occurring the moderate heterogeneities, stratification analysis was subsequently performed and found a significant impact on susceptibility only in basal cell cancer, and no association was observed in the other subgroups, this indicated that the heterogeneities may be results from the basal cell cancer. For *XPF* rs3136038 polymorphism, a reduced overall cancer risk was noted in the additive model. In the subgroup analysis, harboring rs3136038 TT genotype, dominant model or recessive model significantly reduced cancer risk in the digestive system cancer, however, no association was observed in the other subgroup. These results hint that genetic variants involved in the carcinogenesis dependent on the cancer type-specificity such as cancer subgroup based on organ systems. In addition, no significant association was determined in *XPC* rs1870134 polymorphism and cancer susceptibility. Only one report demonstrated that *XPC* rs1870134 polymorphism is a cancer risk biomarker for prostate cancer [@B29], which suggested more and further research about this association is necessary.

Werner syndrome protein (WRN) is an important RecQ helicase that recognizes specific DNA structures and participates in DNA repair, replication, and genome stability through different pathways [@B16]. Overexpression of WRN is found in several cancer cell lines, and depletion of WRN protein induces cell death in these cells [@B77]. It is assumed that *WRN* genetic variants such as rs1346044 and rs1801195 may correlate with the susceptibility to cancers [@B64]-[@B75]. In our pooled meta-analysis, 5 studied of 3162 cases and 3142 controls for SNP rs1801195, 11 studies with 6538 cases and 7657 controls for SNP rs1346044 were included. Despite the fact that no association observed between overall cancer risk and these 2 SNPs, further stratification analysis found that increased cancer risk in the genital system patients with rs1801195 TT genotype and breast cancer with rs1346044 CC genotype. Both of the rs1346044 and rs1801195are located at Exon region of *WRN* gene, which contains a T to C substitution for rs1346044 (amino acids change: Cys1367Arg), and a T to G substitution for rs1801195 (amino acids change: Leu1074Phe). It is plausible that the amino acids substitution can change the tertiary structure, which results in the direct binding of BRCA1 and then alter the function of the WRN protein in facilitating the carcinogenesis [@B80], [@B81], which only partially explains the cancer risk associated with these SNPs because of not all types of cancer susceptibility observed, and further studies are needed.

Regardless of the fact that no previous bioinformatics analysis and meta-analysis to date that systematically investigated the correlation between the seven SNPs of the DNA damage response genes and risk of cancer. Some limitations are taken into account. First, although overall recruited eligible studies sample is relatively large, only 4 studies were included for the SNPs *XPA* rs10817938 and *WRN* rs1801195, thus the results cannot be rule out the possibility of fortuitous considering the limited small size for these two SNPs. Second, in the present review, all the 58 studies included were searched available in the languages of Chinese or English, which may lead to the main source of publication bias because of publications of other languages including the relevant SNPs studies. Third, seven SNPs located in the 5\'UTR or Exon of the DNA repair genes were selected, however, the SNPs of 3\'UTR or Intron region was not included. Therefore, limited SNPs were not sufficient to elucidate most genetic information of DNA repair process, more SNPs should be included, and interaction with other factors such as environmental factor should be investigated in the future analysis.

In conclusion, this included 33 types of cancers bioinformatics analysis,*XPA* and *XPC* mRNA expression reduced, *XPD*,*XPF*, and *WRN* expression increased based on the GEO dataset. Further meta Z-scores prognosis analysis displayed that overexpression of *XPA* or *XPC* had a better impact on overall survival time, nevertheless, elevated *XPD*, *XPF*, and *WRN* expression showed a worse influence on prognosis. The meta-analysis included the latest publications exhibit that harboring SNPs *XPA* rs10817938 and *XPD* rs238406 were significantly associated with increased overall cancer risk, however, polymorphisms of *XPA* rs2808668 in overall cancer analysis and *XPF* rs3136038 in the digestive system remarkably reduced the susceptibility of cancer. In addition, no relationship to the overall cancer risk was observed in SNPs of *XPC* rs1870134, *WRN* rs1346044 and rs1801195 to data included literature. Therefore, these findings provide the most valid cancer prevalence estimate to date, which is a necessary foundations piece for further research in this field.
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![The relative mRNA expressions of the DNA repair genes in cancer tissues and normal samples (A).The association of these genes expression with cancer, the redder of the square, and the more related with cancer (B).](jcav10p3593g001){#F1}

![GEO and Array Express datasets shows the DNA repair genes had an impact on clinical outcomes by using of meta survival Z-scores (A) and log-rank test and multivariate Cox proportional hazards regression model analysis (B).](jcav10p3593g002){#F2}

![*cBioPortal* software exhibits the characteristic of the DNA repair genes in the total genetic alteration (A), the alteration frequency (B), and duplicate polymorphisms or somatic mutations (C) based on TCGA database (Case Set: 63658 patients/65690 samples).](jcav10p3593g003){#F3}

![Forest plots manifests the relationship of cancer risk with polymorphism of *XPA* rs10817938 (A), *XPA* rs2808668 (B), *XPC* rs1870134 (C), *XPD* rs238406 (D), *XPF* rs3136038 (E), WRN rs1801195(F) and rs1346044(G) in overall analysis and stratification analysis under dominant model. Estimates of OR (95%CIs) are plotted with a box and a horizontal line for each study. ◇pooled ORs (95% CIs).](jcav10p3593g004){#F4}

![Forest plots displays the association of cancer risk with polymorphism of *XPA* rs10817938 (A), *XPA* rs2808668 (B), *XPC* rs1870134 (C), *XPD* rs238406 (D), *XPF* rs3136038 (E), *WRN* rs1801195(F) and rs1346044(G) in overall analysis and stratification analysis under recessive model. Estimates of OR (95%CIs) are plotted with a box and a horizontal line for each study. ◇, pooled ORs (95% CIs).](jcav10p3593g005){#F5}

###### 

Meta-analysis of the association between genetic polymorphisms of DNA repair pathway and cancer risk by dominant and recessive models

  Variables               *P*^z\*^   Dominant OR(95%CI)   *P*^het\#^   *I*^2\#^(%)   *P*^z\*^   Recessive OR(95%CI)   *P*^het\#^   *I*^2\#^(%)
  ----------------------- ---------- -------------------- ------------ ------------- ---------- --------------------- ------------ -------------
  *XPA* rs10817938                   CC/CT VS. TT                                               CC VS. CT/TT                       
  Digestive system^†^     0.008      1.37 (1.08,1.73)     0.03         66.3          0.06       1.60 (0.98,2.62)      0.211        33.5
  Overall                 0.008      1.37 (1.08,1.73)     0.03         66.3          0.06       1.60 (0.98,2.62)      0.211        33.5
  *XPA* rs2808668                    CC/CT VS. TT                                               CC VS. TT/TC                       
  Digestive system^†^     0.61       1.04 (0.91,1.18)     0.74         0.0           0.03       1.18 (1.02,1.37)      0.91         0.0
  Others                  0.96       1.01 (0.78,1.31)     0.69         0.0           0.000      0.63 (0.49,0.82)      0.33         0.0
  Overall                 0.64       1.029 (0.91,1.16)    0.89         0.0           0.94       1.01 (0.80,1.37)      0.006        64.3
  *XPC* rs1870134                    CC/CG VS. GG                                               CC VS. GG/GC                       
  Digestive system^†^     0.45       1.03 (0.94,1.14)     0.66         0.0           0.56       0.93 (0.71,1.20)      0.21         34.2
  Others                  0.79       0.96 (0.71,1.30)     0.04         69.0          0.66       0.88 (0.51,1.53)      0.09         58.8
  Overall                 0.84       0.99 (0.88,1.11)     0.09         44.1          0.46       0.92 (0.74,1.15)      0.15         36.4
  *XPD* rs238406                     AA/AC VS.CC                                                AA VS. CC/CA                       
  Nervous system^§^       0.70       1.10 (0.68,1.79)     0.03         72.2          0.33       1.36 (0.72,2.57)      0.01         77.5
  Basal cell cancer       0.11       1.19 (0.96,1.48)     0.35         5.1           0.03       1.30 (1.03,1.65)      0.68         0.0
  Digestive system^†^     0.20       0.91 (0.79,1.05)     0.64         0.0           0.08       1.15 (0.98,1.35)      0.42         0.0
  Urinary system^£^       0.56       1.15 (0.75,1.85)     0.03         79.2          0.68       1.24 (0.45,3.45)      0.000        93.4
  Genital system^¥^       0.62       1.09 (0.77,1.53)     0.02         61.8          0.06       1.36 (0.98,1.87)      0.08         49.3
  Respiratory system^¶^   0.94       0.99 (0.74,1.32)     0.88         0.0           0.03       1.65 (1.04,2.60)      0.99         0.0
  Others                  0.72       0.97 (0.83,1.14)     0.06         60.5          0.64       1.08 (0.78,1.51)      0.06         60.5
  Overall                 0.65       1.03 (0.93,1.13)     0.04         37.0          0.007      1.21 (1.05,1.40)      0.000        61.0
  *XPF* rs3136038                    TT/TC VS. CC                                               TT VS. CC/CT                       
  Respiratory system^¶^   0.34       0.92 (0.78,1.09)     0.17         49.9          0.96       0.94 (0.59,2.08)      0.01         77.1
  Nervous system^§^       0.75       1.02 (0.89,1.18)     0.98         0.0           0.19       0.83 (0.61,1.11)      0.34         7.4
  Digestive system^†^     0.02       0.81 (0.68,0.96)     0.62         0.0           0.03       0.70 (0.52,0.96)      0.28         12.8
  others                  0.01       0.69 (0.53,0.90)     0.98         0.0           0.74       1.06 (0.76,1.48)      0.18         44.7
  Overall                 0.02       0.89 (0.81,0.98)     0.19         28.1          0.32       0.88 (0.73,1.07)      0.05         47.6
  *WRN* rs1801195                    GT/TT VS. GG                                               TT VS. GG/GT                       
  Genital system^¥^       0.30       0.92 (0.78,1.08)     0.98         0.0           0.001      1.44 (1.17,1.78)      0.49         0.0
  Others                  0.85       1.01 (0.89,1.16)     0.80         0.0           0.81       0.98 (0.84,1.15)      0.69         0.0
  Overall                 0.63       0.97(0.88,1.08)      0.82         0.0           0.21       1.17 (0.91,1.51)      0.03         66.9
  *WRN* rs1346044                    CC/CT VS.TT                                                CC VS. TT/TC                       
  Breast system           0.02       1.14 (1.02,1.28)     0.07         58.4          0.03       1.37 (1.03,1.83)      0.40         0.0
  Digestive system^†^     0.26       1.22 (0.86,1.72)     0.42         0.0           0.35       0.62 (0.23,1.68)      0.004        82.0
  Others                  0.78       0.95 (0.64,1.40)     0.004        82.0          0.57       0.87 (0.55,1.39)      0.79         0.0
  Overall                 0.27       1.08 (0.94,1.25)     0.001        65.5          0.97       1.01 (0.72,1.41)      0.01         58.1

\****P*^z^**: the significance of the pooled OR was determined by Z-test, and *P* \<0.05 was considered as statistically significant. \#***P*^het^** and ***I*^2^** were calculated by Chi square-based Q-test.

^¶^Respiratory system cancer: lung cancer; ^£^Urinary system cancer: bladder cancer; †Digestive system cancer: gastric cancer, ESCC, hepatocellular cancer, colorectal cancer, laryngeal cancer, OSCC, pancreastic cancer; ^§^Nervous system cancer: glioma; ^¥^Genital system cancer: breast cancer, prostate cancer.
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